KEIO RESEARCHERS INFORMATION SYSTEM

Career 【 Display / hide 】

Career 【 Display / hide 】

• 2000.05

  -

  2002.04

  慶應義塾大学医学部, 内科学, 研修医

• 2002.05

  -

  2003.05

  川崎市立川崎病院, 内科, 医員

• 2003.06

  -

  2004.05

  水戸赤十字病院, 内科, 医員

• 2004.06

  -

  2010.01

  慶應義塾大学医学部, 内科学(呼吸器), 助手

• 2007.01

  -

  2010.01

  慶應義塾大学医学部, 微生物学・免疫学, 研究員

display all >>

Academic Background 【 Display / hide 】

Academic Background 【 Display / hide 】

• 2000.03

  Keio University, Faculty of Medicine, 医学科

  University, Graduated

Academic Degrees 【 Display / hide 】

Academic Degrees 【 Display / hide 】

• 博士, Keio University, Dissertation, 2008.06

Licenses and Qualifications 【 Display / hide 】

Licenses and Qualifications 【 Display / hide 】

• 医師免許, 2000.04

Research Areas 【 Display / hide 】

Research Areas 【 Display / hide 】

• Life Science / Respiratory medicine

• Life Science / Infectious disease medicine

Research Keywords 【 Display / hide 】

Research Keywords 【 Display / hide 】

• Mycobacteriosis

Books 【 Display / hide 】

Books 【 Display / hide 】

• EBM呼吸器疾患の治療2016-2017

  Nishimura Tomoyasu, 中外医学社, 2016.01

  Scope: Interferon Gamma Release Assayの有用性は？

• 新 呼吸器専門医テキスト

  Nishimura Tomoyasu, 南江堂, 2015.04

  Scope: 肺結核症

• 内科研修マニュアル　改訂第2版

  Nishimura Tomoyasu, 南江堂, 2006.07

  Scope: 市中肺炎/院内肺炎

Papers 【 Display / hide 】

Papers 【 Display / hide 】

• The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals

  Uwamino Y., Yokoyama T., Shimura T., Nishimura T., Sato Y., Wakui M., Kosaki K., Hasegawa N., Murata M.

  Vaccine （Vaccine)  40 （ 13 ） 1928 - 1931 2022.03

  ISSN  0264410X

  　View Summary

  The reduced vaccine efficacy against the SARS-CoV-2 variant lineage B. 1.351 (beta variant) containing the E484K and N501Y mutations is well known. The E484K mutation in SARS-CoV-2 is thought to be responsible for weakened humoral immunity. Vaccine efficacy against the R.1 lineage, which contains the E484K mutation but not the N501Y mutation, is uncertain. Serum samples were collected from 100 healthy Japanese participants three weeks after receiving the second dose of the BNT162b2 vaccine, and serum neutralization antibody titers were measured against five SARS-CoV-2 variants. The geometric mean neutralization titers measured for the original and R.1 lineages were equivalent (91.90 ± 2.40 and 102.67 ± 2.28, respectively), whereas a low titer was measured for the beta variant (18.03 ± 1.92). Although further investigations with other variant strains and serum samples are essential, our results imply that the weakened humoral response is not caused solely by the E484K mutation. (UMIN000043340).

  • Access to Document (DOI)

• Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff

  Uwamino Y., Kurafuji T., Sato Y., Tomita Y., Shibata A., Tanabe A., Yatabe Y., Noguchi M., Arai T., Ohno A., Yokota H., Yamasawa W., Uno S., Nishimura T., Hasegawa N., Saya H., Wakui M., Murata M.

  Vaccine （Vaccine)  40 （ 7 ） 1019 - 1025 2022.02

  ISSN  0264410X

  　View Summary

  Background: SARS-CoV-2 vaccination has started worldwide, including Japan. Although high rates of vaccine response and adverse reactions of BNT162b2 vaccine have been reported, knowledge about the relationship between sex differences and antibody response is limited. Furthermore, it is uncertain whether adverse reactions are associated with the vaccine response. Methods: This prospective observational study included 673 Japanese participants working in a medical school and its affiliated hospital in Tokyo, Japan (UMIN000043340). Serum samples were collected before the first dose and three weeks after the second dose of BNT162b2 vaccine, and antibody titers against the receptor-binding domain of the spike protein of SARS-CoV-2 were measured. Answers to questionnaires about background characteristics and adverse reactions were obtained at the time of sample collection, and the relationship between antibody titers was analyzed. Results: After excluding participants who did not complete receiving two doses of vaccination or two series of serum sample collection, 646 participants were analyzed. Although all participants became sero-positive after vaccination, antibody titers were highly variable among individuals (260.9–57,399.7A U/mL), with a median titer of 13478.0AU/mL. Mean titer was higher in females than in males and higher in young (≤45 years old) participants than in aged (>45 years old) participants. Participants who experienced adverse reactions demonstrated a higher antibody titer after vaccination than those without adverse reactions. Multivariable analysis demonstrated that young age, female sex, and adverse reactions after the second dose were independently related to higher antibody titers after the second dose. Discussion: A favorable antibody response was observed after two doses of BNT162b2 vaccination among mostly healthy Japanese participants, especially among female and young participants. Although further investigation is essential, our results imply that the systemic adverse reactions (i.e., fever and general fatigue) are associated with a higher antibody response that indicates the acquisition of humoral immunity.

  • Access to Document (DOI)

• Evaluation of IS1245 LAMP in Mycobacterium avium and the influence of host-related genetic diversity on its application

  Akapelwa M.L., Kapalamula T.F., Ouchi-Aizu Y., Hang'ombe B.M., Nishiuchi Y., Gordon S.V., Solo E.S., Tamaru A., Nishimura T., Hasegawa N., Morimoto K., Fukushima Y., Suzuki Y., Nakajima C.

  Diagnostic Microbiology and Infectious Disease （Diagnostic Microbiology and Infectious Disease)  101 （ 4 ）  2021.12

  ISSN  07328893

  　View Summary

  Early detection and treatment are paramount for the timely control of Mycobacterium avium infections. Herein, we designed a LAMP assay targeting a widely used species-specific marker IS1245 for the rapid detection of M. avium and evaluated its applicability using human (n = 137) and pig (n = 91) M. avium isolates from Japan. The developed assay could detect as low as 1 genome copy of M. avium DNA within 30 minutes. All 91 (100%) M. avium isolates from pigs were detected positive while all other tested bacterial species were negative. Interestingly, among the 137 clinical M. avium isolates, 41 (30%) were undetectable with this LAMP assay as they lacked IS1245, the absence of which was revealed by PCR and whole-genome sequencing. These findings highlighted genotypic differences in M. avium strains from humans and pigs in Japan and how this diversity can influence the applicability of a detection tool across different geographic areas and hosts.

  • Access to Document (DOI)

• Virucidal effect of the mesoscopic structure of cac-717 on severe acute respiratory syndrome coronavirus-2

  Yokoyama T., Nishimura T., Uwamino Y., Kosaki K., Furusaki K., Onishi R., Onodera T., Haritani M., Sugiura K., Kirisawa R., Hasegawa N.

  Microorganisms （Microorganisms)  9 （ 10 ）  2021.10

  　View Summary

  Here, the virucidal effect of calcium bicarbonate with a mesoscopic structure (CAC-717) on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was determined. Assays showed that CAC-717 had a strong virucidal effect on all examined SARS-CoV-2 isolates, including variant strains. The viral infectivity decreased within 15 s, and the virucidal activity of CAC-717 at a 1:49 ratio was similar to that of ethanol disinfectant. CAC-717 neutralization eliminated this viru-cidal effect, indicating that the alkaline condition of CAC-717 is important for virus inactivation and is an indicator of its mesoscopic structure and virucidal activity. The virucidal effect was observed in the presence of organic matter (bovine serum albumin). CAC-717 is a non-invasive and non-flammable substance with a low environmental burden, and its usefulness as a novel disinfectant has been confirmed.

  • Access to Document (DOI)

• Genome-wide association study in patients with pulmonary Mycobacterium avium complex disease

  Namkoong H., Omae Y., Asakura T., Ishii M., Suzuki S., Morimoto K., Kawai Y., Emoto K., Oler A.J., Szymanski E.P., Yoshida M., Matsuda S., Yagi K., Hase I., Nishimura T., Sasaki Y., Asami T., Shiomi T., Matsubara H., Shimada H., Hamamoto J., Jhun B.W., Kim S.Y., Huh H.J., Won H.H., Ato M., Kosaki K., Betsuyaku T., Fukunaga K., Kurashima A., Tettelin H., Yanai H., Mahasirimongkol S., Olivier K.N., Hoshino Y., Koh W.J., Holland S.M., Tokunaga K., Hasegawa N.

  European Respiratory Journal （European Respiratory Journal)  58 （ 2 ）  2021.08

  ISSN  09031936

  　View Summary

  Rationale Nontuberculous mycobacteria (NTM) are environmental mycobacteria that can cause a chronic progressive lung disease. Although epidemiological data indicate potential genetic predisposition, its nature remains unclear. Objectives We aimed to identify host susceptibility loci for Mycobacterium avium complex (MAC), the most common NTM pathogen. Methods This genome-wide association study (GWAS) was conducted in Japanese patients with pulmonary MAC and healthy controls, followed by genotyping of candidate single-nucleotide polymorphisms (SNPs) in another Japanese cohort. For verification by Korean and European ancestry, we performed SNP genotyping. Results The GWAS discovery set included 475 pulmonary MAC cases and 417 controls. Both GWAS and replication analysis of 591 pulmonary MAC cases and 718 controls revealed the strongest association with chromosome 16p21, particularly with rs109592 (p=1.64×10−13, OR 0.54), which is in an intronic region of the calcineurin-like EF-hand protein 2 (CHP2). Expression quantitative trait loci analysis demonstrated an association with lung CHP2 expression. CHP2 was expressed in the lung tissue in pulmonary MAC disease. This SNP was associated with the nodular bronchiectasis subtype. Additionally, this SNP was significantly associated with the disease in patients of Korean (p=2.18×10−12, OR 0.54) and European (p=5.12×10−03, OR 0.63) ancestry. Conclusions We identified rs109592 in the CHP2 locus as a susceptibility marker for pulmonary MAC disease.

  • Access to Document (DOI)

display all >>

Papers, etc., Registered in KOARA 【 Display / hide 】

Papers, etc., Registered in KOARA 【 Display / hide 】

• Elucidation of the host immune response to nontuberculous mycobacterial cell wall lipids

  Nishimura, Tomoyasu

  科学研究費補助金研究成果報告書 2018

• Elucidation of miRNA-mediated pathophysiology of MAC pulmonary disease

  Nishimura, Tomoyasu

  科学研究費補助金研究成果報告書 2018

• Tuberculosis countermeasures for the top global university project in Keio University

  Nishimura, Tomoyasu

  学事振興資金研究成果実績報告書 （慶應義塾大学)  2017

• Association of sex steroid hormones and non-tuberculous mycobacteriosis

  Nishimura, Tomoyasu

  科学研究費補助金研究成果報告書 2017

• Basic research for the development of new therapies for tuberculosis

  Nishimura, Tomoyasu

  科学研究費補助金研究成果報告書 2015

display all >>

Presentations 【 Display / hide 】

Presentations 【 Display / hide 】

• 外国人留学生を対象とした結核感染調査

  西村知泰，森正明，牧野伸司，広瀬寛，和井内由充子，横山裕一，武田彩乃，畔上達彦，後藤伸子，河邊博史

  第116回日本内科学会総会・講演会 (名古屋) , 

  2019.04

  , 

  Poster presentation

• 肺MAC症の新規検査法

  Nishimura Tomoyasu

  第101回日本細菌学会関東支部総会 (東京) , 

  2018.11

  , 

  Symposium, workshop panel (nominated)

• アスペルギルス沈降抗体陽性である肺Mycobacterium avium complex症患者の臨床的特徴

  鈴木翔二, 朝倉崇徳, 南宮湖, 岡森慧, 八木一馬, 鎌田浩史, 舩津洋平, 中野泰, 西村知泰, 石井誠, 海老原全, 別役智子, 長谷川直樹．

  第58回日本呼吸器学会学術講演会 (大阪) , 

  2018.04

  , 

  Poster presentation

• 大学生における先天性心疾患の管理状況

  牧野伸司, 和井内由充子, 武田彩乃, 畔上達彦, 広瀬寛, 西村知泰, 横山裕一, 河邊博史, 森正明．

  第115回日本内科学会年次学術講演会 (京都) , 

  2018.04

  , 

  Poster presentation

• 当大学医学部留学生に対するImmunization Recordの運用と考察

  武藤志保, 横山裕一, 弦巻美保, 齋藤圭美, 西村知泰, 森正明, 河邊博史．

  第55回全国大学保健管理研究集会 (宜野湾) , 

  2017.11

  , 

  Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide 】

Research Projects of Competitive Funds, etc. 【 Display / hide 】

• 医療従事者における新型コロナウイルスの感染状況調査

  2020.10

  -

  2021.09

  大和証券ヘルス財団, Research grant, Principal investigator

• 慶應義塾における新型コロナウイルス感染症対策

  2020.08

  -

  2021.03

  慶應義塾学事振興資金, Research grant, Principal investigator

• 肺MAC症の病態における菌細胞壁脂質の役割

  2019.06

  -

  2022.05

  武田科学振興財団, 医学系研究助成, Research grant, Principal investigator

• 肺非結核性抗酸菌症患者のゲノム情報に基づいた病態解明

  2019.04

  -

  2022.03

  文部科学省・日本学術振興会, 科学研究費補助金, Research grant, Coinvestigator(s)

• 菌細胞壁脂質に着目した肺MAC症の病態解明

  2019.04

  -

  2022.03

  文部科学省・日本学術振興会, 科学研究費補助金, Research grant, Principal investigator

display all >>

Courses Taught 【 Display / hide 】

Courses Taught 【 Display / hide 】

• INFECTIOUS DISEASES

  2022

• INFECTIOUS DISEASES

  2021

• INFECTIOUS DISEASES

  2020

• MEDICINE IN MODERN SOCIETY 2

  2019

• INFECTIOUS DISEASES

  2019

Courses Previously Taught 【 Display / hide 】

Courses Previously Taught 【 Display / hide 】

• 感染症学

  Keio University

  2018.04

  -

  2019.03

  , 

  Full academic year, Other, Lecture, Lecturer outside of Keio

• 現代社会と医学Ⅱ

  Keio University

  2018.04

  -

  2019.03

  , 

  Full academic year, Other, Lecture, Within own ｆaculty

Social Activities 【 Display / hide 】

Social Activities 【 Display / hide 】

• 平成27年度外務省巡回医師団

  2016.02

  -

  2016.03

• 平成26年度外務省巡回医師団

  2015.01

  -

  2015.02

Memberships in Academic Societies 【 Display / hide 】

Memberships in Academic Societies 【 Display / hide 】

• 日本免疫学会

  　

• 日本内科学会

  　

• 日本呼吸器学会

  　

• 日本呼吸器内視鏡学会

  　

• 日本感染症学会

  　

display all >>

Committee Experiences 【 Display / hide 】

Committee Experiences 【 Display / hide 】

• 2016.04

  -

  Present

  評議員, 日本感染症学会